Generics pharmaceutical company Zentiva, together with private equity investors Advent and GTCR, on Thursday announced the sale of Zentiva by Advent to GTCR.

Since acquiring Zentiva from Sanofi in 2018, Advent has worked closely with the management team to transform the business, whilst investing to expand Zentiva's portfolio of medicines and manufacturing footprint, both organically and through targeted M&A.

GTCR is a US-based private equity firm with a history of investments in the healthcare sector and domain expertise in the pharmaceutical industry.

Subject to customary regulatory approvals, the transaction is expected to close in early 2026.